GlobeNewswire PharmaOriginal article
Boehringer Ingelheim strengthens obesity pipeline as potential first-in-class triple receptor agonist BI 3034701 enters Phase II development
Phase 2BI 3034701Positive
AI Analysis
Summary
Boehringer Ingelheim announces the initiation of a Phase II clinical trial for BI 3034701, a potential first-in-class triple GLP-1/GIP/NPY2 receptor agonist, in patients with obesity and overweight, advancing its cardiometabolic pipeline.
Clinical Trial Data
Phase
Phase II
Importance:6/10
Sentiment:
0.60
obesityGLP-1 receptor agonisttriple receptor agonistcardiometabolicPhase 2first-in-class
Related Companies
Read the original article
Published by GlobeNewswire Pharma on July 16, 2026 5:00 AM